CCR2 and neoplasm: Antibodies designed to broadly deplete TAMs, such as CCL2/CCR2 and CSF-1/CSF1-R neutralising mAbs have performed poorly in the clinic as single agents, characterised by both a lack of effect on specific pro-tumoural subsets and collateral inhibition of anti-tumour TAM activity.